The record
| Class | dual agonist |
|---|---|
| Also known as | - |
| Chain length | - |
| Molecular weight | 4,813.52 Da |
| Half-life | 120 hours |
| Route | - |
| Studied for | - |
| Research use | - |
| What has been shown | - |
| How it works | GLP-1/GIP dual receptor agonist |
| Patent status | - |
| Regulatory status | - |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Fat Loss Signaling Environment (affection, 35%)
- Glucose Regulation Support (affection, 100%)
- Appetite Regulation Environment (affection, 84%)
- Cardiovascular risk reduction in T2DM (illness, 60%)
- CV risk reduction in T2D with CVD (illness, 60%)
- Investigational for obesity/chronic weight management and metabolic disease (illness, 40%)
- NASH/fatty liver (illness, 60%)
- Obesity/weight management (illness, 36%)
- Type 2 diabetes (illness, 60%)
- Type 2 diabetes mellitus (illness, 60%)
- Weight management (illness, 60%)
- High blood sugar (symptom, 100%)